Apraglutide
GLP-2 analog for short bowel syndrome and intestinal rehabilitation. Promotes intestinal growth, enhances nutrient absorption, and reduces parenteral nutrition dependence in short gut syndrome.
Apraglutide is a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog designed for the treatment of short bowel syndrome (SBS). It features a unique structural modification with an extended half-life, allowing for once-weekly dosing while promoting intestinal adaptation, enhancing nutrient absorption, and reducing parenteral support dependency in SBS patients.
| Parameter | Specification |
| CAS | 1295353-98-8 |
| Molecular Formula | C₁₇₂H₂₆₃N₄₃O₅₂ |
| Molecular Weight | 3765.25 g/mol |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Short bowel syndrome, intestinal failure, mucosal healing |
| CAS | 1295353-98-8 |
|---|---|
| Applications | GLP-2, Intestinal Repair, Mucosal Growth, Short Bowel Syndrome |
Related products
-
Pramlintide
CAS: 196078-30-5 -
Survodutide
CAS: 2805997-46-8Applications: Liver Fat, NASH, obesity management, Type 2 diabetes -
Abarelix
CAS: 183552-38-7Applications: Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression -
Alarelin
CAS: 79561-22-1Applications: Assisted Reproduction, Endometriosis, Hormone-dependent Tumors, Uterine Fibroids